00:00
If we suspect HIV, we should diagnose and treat all the opportunistic infections this patient
have. We should generally attempt to use combination antiretroviral therapy, cART or HAART.
00:15
This means that patients will have at least 3 active antiretrovirals from at least 2 different
classes of drugs. The reason why we're treating this virus this way is because with just monotherapy,
the virus may mutate and become resistant very quickly. Remember, in an actively infected
individual, literally billions of copies are being made every day, and the chances of a resistant
form are much higher when there’s monotherapy. So, there are many different classes of HIV
medication and I want to go through them generally. We have entry inhibitors, fusion inhibitors,
non-nucleoside reversed transcriptase inhibitors, nucleoside reverse transcriptase inhibitors,
integrase inhibitors, and protease inhibitors. All of these drugs are acting at different stages in
viral replication, and you can see here examples of a few that are preventing certain stages of
the life cycle of that virus as it grows within the human body. So, let’s go through some disease
complications of untreated HIV and treated HIV. So, in untreated HIV, patients can get <i>P. jirovecii</i>
which we used to call PCP pneumonia, they may get CMV, HSV, they may get bacterial infections,
fungal infections, or often tuberculosis. In treated HIV, we worry about side effects. Examples
may be medication side effects, they may have nausea, rash, hypersensitivity reactions,
neuropsychiatric symptoms, lipodystrophy may happen as a result of medication side effects
and patients may develop resistance to meds leading them back into the untreated category.
02:03
So, the lives of these patients can be quite challenging. With appropriate care, the long-term
prognosis in HIV is excellent. It’s not an easy life but right now, life expectancy in the United
States is quite good. There are certain things that _____ a better survival rate, and a better
life in terms of patients with HIV. Perhaps the most important is earlier detection and treatment.
02:32
If patients are diagnosed early and treated early, they are more likely to be able to live a long
and productive life. Patients who have less immunosuppression will generally have better survival
likelihood, so that happens earlier in disease. Patients who are compliant with therapy will
generally live a long time, and in adolescents it's very hard sometimes to get them on board
regarding compliance. So, counseling and discussion with these children are incredibly important.
03:06
The lower your viral load, the more likely your prolonged survival is as well. So, let’s talk about
how we prevent HIV. In newborns, it’s better when there are laws in each state that are opt
out instead of opt in regarding testing. What this generally means is there are some states in
the United States where pregnant mothers are going to get their HIV test and they have to sign
a special piece of paper. That’s opt in. In other states, patients come into the hospital to see
for their general prenatal care and they are offered HIV testing in the same phrase as they're
offered all their other testing that happens during pregnancy. They may choose not to get HIV
tested, that is their right, but it’s offered as a result of routine screening. As a result, there is
not an extra signature. In states with opt out testing instead of opt in testing, rates of
pregnancy testing for HIV are much higher, and if we can test women, they are more likely to
know their status at the time of delivery which then prevents transmission of the virus. In a
few states such as New York, Illinois, Connecticut, Rhode Island, there is mandated newborn
screening as well. This means that testing of the child at the time of birth is mandated if there’s
no test for the mother available to the physician. This happens right at birth, and then if the
child is positive, HIV care is initiated. In states where this happens, prenatal testing actually
goes up much higher. This is probably because in the office setting, the obstetrician says, “We’ll
test you for HIV,” and the mother says, “I’m not sure if I want to,” and he says, “Okay, but if
you don’t, the baby is going to be tested anyway,” and then almost all mothers will say, “Oh,
well in that case, just test me.” This then allows us to really understand exactly what’s going
on. We should treat pregnant women to reduce viral load at birth. The treatment of pregnant
women dramatically reduces newborn infection rates from 25% to less than 2%. In developing
countries where there is more poverty, we tend to recommend continuing breastfeeding. This
is because the rate of death from starvation may be higher than the rate of HIV transmission
through breastfeeding. Remember, the bulk of vertical transmission is through the birth process,
not through breastfeeding. However, in the United States where there are alternatives that are
available to poor people such as Wick, we do not recommend breastfeeding in HIV-positive women
because in this case, there are easy alternatives for infant nutrition. So, each country has a
different approach to whether breastfeeding is recommended depending on the resources available
to people regarding formula provision. Now, prevention of HIV in adolescents and adults is a
little bit different. For this, we must recommend condom use and we should be providing this
advice to all adolescents and adults regardless of their beliefs and circumstances, the availability
of condom use is critical to reducing the population burden of HIV. Additionally, we should have
routine screening. Again, if a patient is aware of their HIV status, they are much less likely to
actually spread the disease. They are more likely to reliably use condoms and they are more
likely to not share needles. As such, awareness of your status is critically important. Right now
in America, 1 in 4 adults or adolescents with HIV is unaware that they have the disease and
those individuals are responsible for more than half of new infections. We can do these things
through community outreach programs and that’s what’s important for us to do, for us to fund
and have community outreach programs. So, that’s my review of pediatric HIV and HIV in general.
07:21
Thanks for your time.